Site Menu

Home

NIH Human Embryonic Stem Cell Registry
Research Using These Lines is Eligible for NIH Funding

The lines listed below are eligible for use in NIH funded research. Those lines that carry disease-specific mutations are noted as such under the line name.

For guidance regarding applications proposing to use hESC see: NIH Guide Notices NOT-OD-10-020 and NOT-OD-10-029.

Eligible Lines: 
Sorted by:
Date/Time: 		398  (in 182 Submissions)
NIH Restrictions
09/25/2018 at 08:30 PM
Cell Line NIH Registration
Number
(Use for NIH Applications *) 		Provider NIH Restrictions Ascending Sort Submitting
Organization 		Approval
Date
WA15
(see details) 		0096 WiCell Research Institute (None Entered) WiCell Research Institute 06/09/2011
WA16; Klinefelter Syndrome mutation/abnormal karyotype
(see details) 		0097 WiCell Research Institute (None Entered) WiCell Research Institute 06/09/2011
WA17
(see details) 		0098 WiCell Research Institute (None Entered) WiCell Research Institute 06/09/2011
WA18
(see details) 		0099 WiCell Research Institute (None Entered) WiCell Research Institute 06/09/2011
WA19
(see details) 		0100 WiCell Research Institute (None Entered) WiCell Research Institute 06/09/2011
WA20
(see details) 		0101 WiCell Research Institute (None Entered) WiCell Research Institute 06/09/2011
WA21
(see details) 		0102 WiCell Research Institute (None Entered) WiCell Research Institute 06/09/2011
WA22
(see details) 		0103 WiCell Research Institute (None Entered) WiCell Research Institute 06/09/2011
WA23
(see details) 		0104 WiCell Research Institute (None Entered) WiCell Research Institute 06/09/2011
WA24
(see details) 		0105 WiCell Research Institute (None Entered) WiCell Research Institute 06/09/2011
ESI-035
(see details) 		0129 BioTime, Inc. (None Entered) BioTime, Inc. 08/18/2011
ESI-049
(see details) 		0130 BioTime, Inc. (None Entered) BioTime, Inc. 08/18/2011
ESI-051
(see details) 		0131 BioTime, Inc. (None Entered) BioTime, Inc. 08/18/2011
ESI-053
(see details) 		0132 BioTime, Inc. (None Entered) BioTime, Inc. 08/18/2011
CSES18
(see details) 		0135 Dhruv Sareen, Ph.D. (None Entered) Cedars-Sinai Medical Center 09/27/2011
CSES5; abnormal karyotype
(see details) 		0133 Dhruv Sareen, Ph.D. (None Entered) Cedars-Sinai Medical Center 09/27/2011
CSES6; abnormal karyotype
(see details) 		0134 Dhruv Sareen, Ph.D. (None Entered) Cedars-Sinai Medical Center 09/27/2011
HUES PGD 14; Spinal Muscular Atrophy mutation
(see details) 		0136 Eggan Lab (None Entered) Harvard University 10/11/2011
UM4-6
(see details) 		0147 Gary D. Smith, University of Michigan (None Entered) University of Michigan 02/02/2012
UCLA 7; Patau syndrome/Trisomy 13
(see details) 		0143 Steven Peckman (None Entered) University of California, Los Angeles 01/12/2012
UCLA 8
(see details) 		0144 Steven Peckman (None Entered) University of California, Los Angeles 01/12/2012
UCLA 9
(see details) 		0145 Steven Peckman (None Entered) University of California, Los Angeles 01/12/2012
UCLA 10
(see details) 		0146 Steven Peckman (None Entered) University of California, Los Angeles 01/12/2012
UM9-1PGD; hemophilia B mutation
(see details) 		0154 Gary D. Smith, University of Michigan (None Entered) University of Michigan 05/14/2012
UM11-1PGD; Charcot Marie Tooth disease Type IA mutation
(see details) 		0153 Gary D. Smith, University of Michigan (None Entered) University of Michigan 04/12/2012
HUES PGD 15; possible Huntington's Disease mutation
(see details) 		0149 Eggan Lab (None Entered) Harvard University 02/24/2012
HUES PGD 16; Huntington's Disease mutation
(see details) 		0150 Eggan Lab (None Entered) Harvard University 02/24/2012
GENEA002
(see details) 		0151 Genea Biocells (None Entered) Genea Biocells 03/20/2012
GENEA048; abnormal karyotype
(see details) 		0152 Genea Biocells (None Entered) Genea Biocells 03/20/2012
GENEA017; Huntington's Disease mutation
(see details) 		0166 Genea Biocells (None Entered) Genea Biocells 06/20/2012
GENEA041; Cystic Fibrosis mutation
(see details) 		0167 Genea Biocells (None Entered) Genea Biocells 06/20/2012
GENEA068; Wilm's Tumour mutation
(see details) 		0168 Genea Biocells (None Entered) Genea Biocells 06/20/2012
GENEA018; Huntington's disease mutation
(see details) 		0169 Genea Biocells (None Entered) Genea Biocells 06/20/2012
GENEA024; Facioscapulohumeral muscular dystrophy mutation
(see details) 		0170 Genea Biocells (None Entered) Genea Biocells 06/20/2012
GENEA040; cystic fibrosis mutation
(see details) 		0171 Genea Biocells (None Entered) Genea Biocells 06/20/2012
GENEA060; Van Hippel Lindau mutation
(see details) 		0172 Genea Biocells (None Entered) Genea Biocells 06/20/2012
GENEA061; Van Hippel Lindau mutation
(see details) 		0173 Genea Biocells (None Entered) Genea Biocells 06/20/2012
GENEA064; Charcot Marie Tooth syndrome mutation
(see details) 		0174 Genea Biocells (None Entered) Genea Biocells 06/20/2012
GENEA046; Huntington's Disease mutation
(see details) 		0180 Genea Biocells (None Entered) Genea Biocells 10/05/2012
GENEA049; facioscapulohumeral muscular dystrophy mutation
(see details) 		0183 Genea Biocells (None Entered) Genea Biocells 11/02/2012
GENEA050; facioscapulohumeral muscular dystrophy mutation
(see details) 		0184 Genea Biocells (None Entered) Genea Biocells 11/02/2012
GENEA058; Becker Muscular Dystrophy mutation
(see details) 		0199 Genea Biocells (None Entered) Genea Biocells 01/08/2013
GENEA069; Vitelliform Macular Dystrophy mutation
(see details) 		0181 Genea Biocells (None Entered) Genea Biocells 10/05/2012
GENEA070; Vitelliform Macular Dystrophy mutation
(see details) 		0182 Genea Biocells (None Entered) Genea Biocells 10/05/2012
GENEA059; BRCA1 mutation
(see details) 		0175 Genea Biocells (None Entered) Genea Biocells 07/09/2012
GENEA065; Infantile Neuroaxonal Dystrophy mutation
(see details) 		0200 Genea Biocells (None Entered) Genea Biocells 01/08/2013
GENEA062; Charcot-Marie-Tooth mutation
(see details) 		0187 Genea Biocells (None Entered) Genea Biocells 12/14/2012
GENEA063; Charcot-Marie-Tooth mutation
(see details) 		0188 Genea Biocells (None Entered) Genea Biocells 12/14/2012
GENEA066; myotonic muscular dystrophy mutation
(see details) 		0189 Genea Biocells (None Entered) Genea Biocells 12/14/2012
GENEA067; myotonic muscular dystrophy mutation
(see details) 		0190 Genea Biocells (None Entered) Genea Biocells 12/14/2012
GENEA071; incontinentia pigmenti mutation
(see details) 		0191 Genea Biocells (None Entered) Genea Biocells 12/14/2012
GENEA072; juvenile retinoschisis mutation
(see details) 		0192 Genea Biocells (None Entered) Genea Biocells 12/14/2012
GENEA073; alpha thalassaemia mutation
(see details) 		0193 Genea Biocells (None Entered) Genea Biocells 12/14/2012
GENEA074; autosomal dominant torsion dystonia mutation
(see details) 		0194 Genea Biocells (None Entered) Genea Biocells 12/14/2012
Elf1
(see details) 		0156 Susan Langbehn (None Entered) University of Washington 05/15/2012
I3 (TE03)
(see details) 		0204 Technion R&D foundation (None Entered) Technion R&D Foundation 03/18/2013
I4 (TE04)
(see details) 		0205 Technion R&D foundation (None Entered) Technion R&D Foundation 03/18/2013
I6 (TE06)
(see details) 		0206 Technion R&D foundation (None Entered) Technion R&D Foundation 03/18/2013
UM15-4 PGD; Hydroxysteroid Dehydrogenase 4 Deficiency mutation
(see details) 		0161 University of Michigan, Gary D. Smith (None Entered) University of Michigan 05/31/2012
NMR-1
(see details) 		0159 Rick A. Wetsel, Ph.D. (None Entered) University of Texas Hlth Sci Ctr Houston 05/31/2012
UM38-2 PGD; Hypertrophic Cardiomyopathy mutation
(see details) 		0155 Gary D. Smith, University of Michigan (None Entered) University of Michigan 05/14/2012
HS346
(see details) 		0201 Karolinska Institute (None Entered) Karolinska Institute 03/18/2013
HS401
(see details) 		0202 Karolinska Institute (None Entered) Karolinska Institute 03/18/2013
HS420
(see details) 		0203 Karolinska Institute (None Entered) Karolinska Institute 03/18/2013
UM14-1
(see details) 		0162 Gary D. Smith/University of Michigan (None Entered) University of Michigan 05/31/2012
UM14-2
(see details) 		0163 Gary D. Smith/University of Michigan (None Entered) University of Michigan 05/31/2012
UM17-1 PGD; Huntington's disease mutation
(see details) 		0160 Gary D. Smith/University of Michigan (None Entered) University of Michigan 05/31/2012
HS799; Huntington's disease mutation
(see details) 		0207 Karolinska Institute (None Entered) Karolinska Institute 03/18/2013
WCMC-37; Fragile X mutation
(see details) 		0211 Weill Cornell Medical College- Nikica Zaninovic, PhD and Zev Rosenwaks, MD (None Entered) Joan & Sanford I. Weill Medical College of Cornell University 06/27/2013
UM29-2 PGD; Aniridia mutation
(see details) 		0164 Gary D. Smith/University of Michigan (None Entered) University of Michigan 06/18/2012
UM29-3 PGD; Aniridia mutation
(see details) 		0165 Gary D. Smith/University of Michigan (None Entered) University of Michigan 06/18/2012
UCLA 11
(see details) 		0185 Steven Peckman (None Entered) University of California, Los Angeles 11/20/2012
UCLA 12
(see details) 		0186 Steven Peckman (None Entered) University of California, Los Angeles 11/20/2012
HUES PGD 2; possible Wiskott-Aldrich Syndrome mutation
(see details) 		0195 Eggan Lab (None Entered) Harvard University 12/14/2012
WA25
(see details) 		0196 WiCell Research Institute (None Entered) WiCell Research Institute 12/14/2012
WA26
(see details) 		0197 WiCell Research Institute (None Entered) WiCell Research Institute 12/14/2012
WA27
(see details) 		0198 WiCell Research Institute (None Entered) WiCell Research Institute 12/14/2012
CR-4
(see details) 		0210 Rick A. Wetsel, Ph.D. (None Entered) University of Texas Hlth Sci Ctr at Houston 05/29/2013
UM57-1 PGD; Multiple Endocrine Neoplasia-Type 2A mutations
(see details) 		0208 Gary D. Smith/University of Michigan (None Entered) University of Michigan 03/26/2013
UM22-2
(see details) 		0209 Gary D. Smith/University of Michigan (None Entered) University of Michigan 03/26/2013
CSC14
(see details) 		0284 NeoStem, Inc. (Irvine) (None Entered) NeoStem, Inc. 09/18/2014
GENEA015
(see details) 		0228 Genea Biocells (None Entered) Genea Biocells 09/30/2013
GENEA016
(see details) 		0229 Genea Biocells (None Entered) Genea Biocells 09/30/2013
GENEA042
(see details) 		0231 Genea Biocells (None Entered) Genea Biocells 09/30/2013
GENEA043
(see details) 		0232 Genea Biocells (None Entered) Genea Biocells 09/30/2013
GENEA047
(see details) 		0230 Genea Biocells (None Entered) Genea Biocells 09/30/2013
GENEA096; Fascioscapulohumeral Muscular Dystrophy mutations
(see details) 		0244 Genea Biocells (None Entered) Genea Biocells 01/29/2014
GENEA090; Huntington's Disease mutations
(see details) 		0245 Genea Biocells (None Entered) Genea Biocells 01/29/2014
GENEA091; Huntington's Disease mutations
(see details) 		0246 Genea Biocells (None Entered) Genea Biocells 01/29/2014
GENEA089; Huntington's Disease mutations
(see details) 		0247 Genea Biocells (None Entered) Genea Biocells 01/29/2014
GENEA097; Multiple Hereditary Exotoses mutations
(see details) 		0248 Genea Biocells (None Entered) Genea Biocells 01/29/2014
GENEA098; Multiple Hereditary Exotoses mutations
(see details) 		0249 Genea Biocells (None Entered) Genea Biocells 01/29/2014
GENEA085 ; Retinitis Pigmentosa mutations
(see details) 		0250 Genea Biocells (None Entered) Genea Biocells 01/29/2014
GENEA082 ; Epidermolysis Bullosa mutations/trisomy 8 and 21
(see details) 		0251 Genea Biocells (None Entered) Genea Biocells 01/29/2014
GENEA078 ; Nemaline myopathy 2 mutations
(see details) 		0252 Genea Biocells (None Entered) Genea Biocells 01/29/2014
GENEA079 ; Nemaline myopathy 2 mutations
(see details) 		0253 Genea Biocells (None Entered) Genea Biocells 01/29/2014
GENEA080 ; Nemaline myopathy 2 mutations
(see details) 		0254 Genea Biocells (None Entered) Genea Biocells 01/29/2014
GENEA081 ; Merosin Deficiency 1A mutations
(see details) 		0255 Genea Biocells (None Entered) Genea Biocells 01/29/2014
GENEA083; Loeys-Dietz Syndrome 2 mutations, MOSAIC (15q11.1-q11.2)
(see details) 		0256 Genea Biocells (None Entered) Genea Biocells 01/29/2014
GENEA084 ; Loeys-Dietz Syndrome 2 mutations
(see details) 		0257 Genea Biocells (None Entered) Genea Biocells 01/29/2014
GENEA086 ; Tuberous Sclerosis 2 mutations
(see details) 		0258 Genea Biocells (None Entered) Genea Biocells 01/29/2014
GENEA087; Tuberous Sclerosis 2 mutations
(see details) 		0259 Genea Biocells (None Entered) Genea Biocells 01/29/2014
GENEA088 ; Simpson Golabi Behmel mutations
(see details) 		0260 Genea Biocells (None Entered) Genea Biocells 01/29/2014
GENEA077; Hypochondroplasia mutations
(see details) 		0261 Genea Biocells (None Entered) Genea Biocells 01/29/2014
GENEA057
(see details) 		0233 Genea Biocells (None Entered) Genea Biocells 09/30/2013
GENEA052
(see details) 		0234 Genea Biocells (None Entered) Genea Biocells 09/30/2013
NYUES12
(see details) 		0235 Christoph Hansis, MD, PhD (None Entered) New York University School of Medicine 12/23/2013
NYUES11; abnormal karyotype
(see details) 		0236 Christoph Hansis, MD, PhD (None Entered) New York University School of Medicine 12/23/2013
NYUES13
(see details) 		0237 Christoph Hansis, MD, PhD (None Entered) New York University School of Medicine 12/23/2013
KCL011
(see details) 		0212 Dusko Ilic, King's College London (None Entered) King's College London 09/19/2013
KCL012; Huntington’s Disease mutations
(see details) 		0213 Dusko Ilic, King's College London (None Entered) King's College London 09/19/2013
KC013; Huntington’s Disease mutations
(see details) 		0214 Dusko Ilic, King's College London (None Entered) King's College London 09/19/2013
KCL032
(see details) 		0266 Dusko Ilic, King's College London (None Entered) King's College London 03/25/2014
KCL033
(see details) 		0267 Dusko Ilic, King's College London (None Entered) King's College London 03/25/2014
KCL034
(see details) 		0268 Dusko Ilic, King's College London (None Entered) King's College London 03/25/2014
KCL015; Von Hippel-Lindau Syndrome mutations
(see details) 		0215 Dusko Ilic, King's College London (None Entered) King's College London 09/19/2013
KCL016; Von Hippel-Lindau Syndrome mutations
(see details) 		0216 Dusko Ilic, King's College London (None Entered) King's College London 09/19/2013
KCL017; Von Hippel-Lindau Syndrome mutations
(see details) 		0217 Dusko Ilic, King's College London (None Entered) King's College London 09/19/2013
KCL018; Myotonic dystrophy type 1 mutations
(see details) 		0218 Dusko Ilic, King's College London (None Entered) King's College London 09/19/2013
KCL021; Cystic Fibrosis mutations
(see details) 		0219 Dusko Ilic, King's College London (None Entered) King's College London 09/19/2013
KCL024; Neurofibromatosis type 1 mutations
(see details) 		0220 Dusko Ilic, King's College London (None Entered) King's College London 09/19/2013
KCL025; Neurofibromatosis type 1 mutations
(see details) 		0221 Dusko Ilic, King's College London (None Entered) King's College London 09/19/2013
KCL026; Spinal muscular atrophy type 1 mutations
(see details) 		0222 Dusko Ilic, King's College London (None Entered) King's College London 09/19/2013
KCL027; Huntington’s Disease mutations
(see details) 		0223 Dusko Ilic, King's College London (None Entered) King's College London 09/19/2013
KCL028; Huntington’s Disease mutations
(see details) 		0224 Dusko Ilic, King's College London (None Entered) King's College London 09/19/2013
KCL029; Wiskott-Aldrich syndrome mutations
(see details) 		0225 Dusko Ilic, King's College London (None Entered) King's College London 09/19/2013
KCL030; beta-thalassemia carrier mutations
(see details) 		0226 Dusko Ilic, King's College London (None Entered) King's College London 09/19/2013
KCL035; beta-thalassemia mutations
(see details) 		0227 Dusko Ilic, King's College London (None Entered) King's College London 09/19/2013
KCL036; Huntington’s Disease mutations
(see details) 		0241 Dusko Ilic, King's College London (None Entered) King's College London 12/23/2013
KCL042; Cystic Fibrosis mutations
(see details) 		0242 Dusko Ilic, King's College London (None Entered) King's College London 12/23/2013
KCL043; Cystic Fibrosis mutations
(see details) 		0243 Dusko Ilic, King's College London (None Entered) King's College London 12/23/2013
KCL023
(see details) 		0262 Dusko Ilic, King's College London (None Entered) King's College London 03/25/2014
KCL031
(see details) 		0263 Dusko Ilic, King's College London (None Entered) King's College London 03/25/2014
KCL022
(see details) 		0264 Dusko Ilic, King's College London (None Entered) King's College London 03/25/2014
KCL038
(see details) 		0265 Dusko Ilic, King's College London (None Entered) King's College London 03/25/2014
KCL037
(see details) 		0269 Dusko Ilic, King's College London (None Entered) King's College London 03/25/2014
KCL019
(see details) 		0270 Dusko Ilic, King's College London (None Entered) King's College London 03/25/2014
KCL020
(see details) 		0271 Dusko Ilic, King's College London (None Entered) King's College London 03/25/2014
KCL040
(see details) 		0272 Dusko Ilic, King's College London (None Entered) King's College London 03/25/2014
KCL041; Turner Syndrome/abnormal karyotype
(see details) 		0273 Dusko Ilic, King's College London (None Entered) King's College London 03/25/2014
KCL039
(see details) 		0274 Dusko Ilic, King's College London (None Entered) King's College London 03/25/2014
NYUES8
(see details) 		0238 Christoph Hansis, MD, PhD (None Entered) New York University School of Medicine 12/23/2013
NYUES9
(see details) 		0239 Christoph Hansis, MD, PhD (None Entered) New York University School of Medicine 12/23/2013
NYUES10
(see details) 		0240 Christoph Hansis, MD, PhD (None Entered) New York University School of Medicine 12/23/2013
UM89-1 PGD; Marfan Syndrome mutation
(see details) 		0276 Gary D. Smith/University of Michigan (None Entered) University Of Michigan 04/09/2014
UM59-2 PGD; Charcot Marie Tooth Type 1A mutation
(see details) 		0275 Gary D. Smith/University of Michigan (None Entered) University of Michigan 04/09/2014
UM63-1
(see details) 		0277 Gary D. Smith/University of Michigan (None Entered) University of Michigan 04/09/2014
UM77-2
(see details) 		0278 Gary D. Smith / University of Michigan (None Entered) University of Michigan 04/09/2014
UM33-4
(see details) 		0279 Gary D. Smith / University of Michigan (None Entered) University of Michigan 04/09/2014
UCLA 13
(see details) 		0293 Steven Peckman (None Entered) University of California, Los Angeles 10/16/2014
UCLA 14
(see details) 		0294 Steven Peckman (None Entered) University of California, Los Angeles 10/16/2014
UCLA 15
(see details) 		0295 Steven Peckman (None Entered) University of California, Los Angeles 10/16/2014
UCLA 16
(see details) 		0296 Steven Peckman (None Entered) University of California, Los Angeles 10/16/2014
HUES 71
(see details) 		0281 Eggan Lab (None Entered) Harvard University 07/31/2014
HUES 72
(see details) 		0282 Eggan Lab (None Entered) Harvard University 07/31/2014
HUES 73
(see details) 		0283 Eggan Lab (None Entered) Harvard University 07/31/2014
HUES 75
(see details) 		0280 Eggan Lab (None Entered) Harvard University 07/31/2014
UM112-1 PGD; Adrenoleukodystrophy mutation
(see details) 		0285 Gary D. Smith / University of Michigan (None Entered) University of Michigan 09/29/2014
UM134-1 PGD; Spinocerebellar Ataxia Type 3 mutation
(see details) 		0286 Gary D. Smith / University of Michigan (None Entered) University of Michigan 09/29/2014
UM90-12 PGS; aneuploid
(see details) 		0287 Gary D. Smith / University of Michigan (None Entered) University of Michigan 09/29/2014
UM78-2
(see details) 		0288 Gary D. Smith / University of Michigan (None Entered) University of Michigan 09/29/2014
UCLA 17
(see details) 		0297 Steven Peckman (None Entered) University of California, Los Angeles 10/16/2014
UCLA 18
(see details) 		0298 Steven Peckman (None Entered) University of California, Los Angeles 10/16/2014
UM76-1 PGS; abnormal karyotype
(see details) 		0289 Gary D. Smith / University of Michigan (None Entered) University of Michigan 09/29/2014
UM114-10
(see details) 		0290 Gary D. Smith / University of Michigan (None Entered) University of Michigan 09/29/2014
UM121-7
(see details) 		0291 Gary D. Smith / University of Michigan (None Entered) University of Michigan 09/29/2014
UM139-2 PGD; Fragile X Syndrome mutation
(see details) 		0292 Gary D. Smith / University of Michigan (None Entered) University of Michigan 09/29/2014
WIN-1
(see details) 		0299 Whitehead Institute for Biomedical Research/Maisam Mitalipova (None Entered) Whitehead Institute for Biomedical Research 10/16/2014
WIN-2
(see details) 		0300 Whitehead Institute for Biomedical Research/Maisam Mitalipova (None Entered) Whitehead Institute for Biomedical Research 10/16/2014
WIN-3
(see details) 		0301 Whitehead Institute for Biomedical Research/Maisam Mitalipova (None Entered) Whitehead Institute for Biomedical Research 10/16/2014
WIN-4
(see details) 		0302 Whitehead Institute for Biomedical Research/Maisam Mitalipova (None Entered) Whitehead Institute for Biomedical Research 10/16/2014
WIN-5
(see details) 		0303 Whitehead Institute for Biomedical Research/Maisam (None Entered) Whitehead Institute for Biomedical Research 10/16/2014
Lis 50_hydrocephaly_3_N
(see details) 		0308 Dalit Ben-Yosef (None Entered) Tel Aviv Sourasky Medical Center 07/16/2015
Lis 51__FXS9_N; Fragile X mutation
(see details) 		0309 Dalit Ben-Yosef (None Entered) Tel Aviv Sourasky Medical Center 07/16/2015
Lis 49_hydrocephaly_2_N
(see details) 		0310 Dalit Ben-Yosef (None Entered) Tel Aviv Sourasky Medical Center 07/16/2015
Lis 48_DMD_6_N; Duchenne Muscular Dystrophy mutation
(see details) 		0311 Dalit Ben-Yosef (None Entered) Tel Aviv Sourasky Medical Center 07/16/2015
Lis47_NF1_2_N; neurofibromatosis type I mutation
(see details) 		0312 Dalit Ben-Yosef (None Entered) Tel Aviv Sourasky Medical Center 07/16/2015
Lis 46_Ichthyosis_2_N
(see details) 		0313 Dalit Ben-Yosef (None Entered) Tel Aviv Sourasky Medical Center 07/16/2015
Lis 45_Ichthyosis_1_N
(see details) 		0314 Dalit Ben-Yosef (None Entered) Tel Aviv Sourasky Medical Center 07/16/2015
Lis 43_connexin_3_N; Non Syndromic Deafness mutation
(see details) 		0315 Dalit Ben-Yosef (None Entered) Tel Aviv Sourasky Medical Center 07/16/2015
Lis 42_NF1_1_N; neurofibromatosis type I mutation
(see details) 		0316 Dalit Ben-Yosef (None Entered) Tel Aviv Sourasky Medical Center 07/16/2015
Lis 41_LTBL_N; leukoencephalopathy
(see details) 		0317 Dalit Ben-Yosef (None Entered) Tel Aviv Sourasky Medical Center 07/16/2015
Lis40_t(13;14)_N
(see details) 		0318 Dalit Ben-Yosef (None Entered) Tel Aviv Sourasky Medical Center 07/16/2015
Lis39_FXS8_N;Fragile X mutation
(see details) 		0319 Dalit Ben-Yosef (None Entered) Tel Aviv Sourasky Medical Center 07/16/2015
Lis38_FXS7_N; Fragile X mutation
(see details) 		0320 Dalit Ben-Yosef (None Entered) Tel Aviv Sourasky Medical Center 07/16/2015
Lis37_FXS_10; Fragile X mutation
(see details) 		0321 Dalit Ben-Yosef (None Entered) Tel Aviv Sourasky Medical Center 07/16/2015
Lis36_t(11;20)_N
(see details) 		0322 Dalit Ben-Yosef (None Entered) Tel Aviv Sourasky Medical Center 07/16/2015
RUES1
(see details) 		0012 The Rockefeller University, Ali Brivanlou (None Entered) The Rockefeller University 12/02/2009
RUES2
(see details) 		0013 The Rockefeller University, Ali Brivanlou (None Entered) The Rockefeller University 12/02/2009
CHB-1
(see details) 		0001 On Hold ** George Q. Daley, M.D., Ph.D. (None Entered) Children's Hospital Corporation 12/02/2009
CHB-2
(see details) 		0002 On Hold ** George Q. Daley, M.D., Ph.D. (None Entered) Children's Hospital Corporation 12/02/2009
CHB-3
(see details) 		0003 On Hold ** George Q. Daley, M.D., Ph.D. (None Entered) Children's Hospital Corporation 12/02/2009
CHB-4
(see details) 		0004 George Q. Daley, M.D., Ph.D. (None Entered) Children's Hospital Corporation 12/02/2009
CHB-5
(see details) 		0005 George Q. Daley, M.D., Ph.D. (None Entered) Children's Hospital Corporation 12/02/2009
CHB-6
(see details) 		0006 George Q. Daley, M.D., Ph.D. (None Entered) Children's Hospital Corporation 12/02/2009
CHB-8
(see details) 		0007 George Q. Daley, M.D., Ph.D. (None Entered) Children's Hospital Corporation 12/02/2009
CHB-9
(see details) 		0008 George Q. Daley, M.D., Ph.D. (None Entered) Children's Hospital Corporation 12/02/2009
CHB-10
(see details) 		0009 George Q. Daley, M.D., Ph.D. (None Entered) Children's Hospital Corporation 12/02/2009
CHB-11
(see details) 		0010 George Q. Daley, M.D., Ph.D. (None Entered) Children's Hospital Corporation 12/02/2009
CHB-12
(see details) 		0011 George Q. Daley, M.D., Ph.D. (None Entered) Children's Hospital Corporation 12/02/2009
WA01 (H1)
(see details) 		0043 WiCell Research Institute (None Entered) WiCell Research Institute 01/29/2010
WA07 (H7)
(see details) 		0061 WiCell Research Institute (None Entered) WiCell Research Institute 04/27/2010
WA09 (H9)
(see details) 		0062 WiCell Research Institute (None Entered) WiCell Research Institute 04/27/2010
WA13 (H13)
(see details) 		0063 WiCell Research Institute (None Entered) WiCell Research Institute 04/27/2010
WA14 (H14)
(see details) 		0064 WiCell Research Institute (None Entered) WiCell Research Institute 04/27/2010
WIBR1
(see details) 		0074 Whitehead Institute for Biomedical Research/Maya Mitalipova (None Entered) Whitehead Institute for Biomedical Research 06/21/2010
WIBR2
(see details) 		0075 Whitehead Institute for Biomedical Research/Maya Mitalipova (None Entered) Whitehead Institute for Biomedical Research 06/21/2010
WIBR3
(see details) 		0079 Whitehead Institute for Biomedical Research/Maya Mitalipova (None Entered) Whitehead Institute for Biomedical Research 11/17/2010
Shef 3
(see details) 		0077 Centre for Stem Cell Biology (None Entered) University of Sheffield 11/17/2010
Shef 6
(see details) 		0078 Centre for Stem Cell Biology (None Entered) University of Sheffield 11/17/2010
MEL-1
(see details) 		0139 Stem Cells Ltd (None Entered) University of Queensland 12/22/2011
MEL-2
(see details) 		0140 Stem Cells Ltd (None Entered) University of Queensland 12/22/2011
MEL-3
(see details) 		0141 Stem Cells Ltd (None Entered) University of Queensland 12/22/2011
MEL-4
(see details) 		0142 Stem Cells Ltd (None Entered) University of Queensland 12/22/2011
HAD-C 100
(see details) 		0123 Benjamin E. Reubinoff (None Entered) Hadassah Hebrew University Medical Center 06/16/2011
HAD-C 102
(see details) 		0124 Benjamin E. Reubinoff (None Entered) Hadassah Hebrew University Medical Center 06/16/2011
HAD-C 106
(see details) 		0125 Benjamin E. Reubinoff (None Entered) Hadassah Hebrew University Medical Center 06/16/2011
WIBR4
(see details) 		0080 Whitehead Institute for Biomedical Research/Maya Mitalipova (None Entered) Whitehead Institute for Biomedical Research 11/17/2010
WIBR5
(see details) 		0081 Whitehead Institute for Biomedical Research/Maya Mitalipova (None Entered) Whitehead Institute for Biomedical Research 11/17/2010
WIBR6
(see details) 		0082 Whitehead Institute for Biomedical Research/Maya Mitalipova (None Entered) Whitehead Institute for Biomedical Research 11/17/2010
CSES2
(see details) 		0106 Dhruv Sareen, Ph.D. (None Entered) Cedars-Sinai Medical Center 06/10/2011
CSES4
(see details) 		0107 Dhruv Sareen, Ph.D. (None Entered) Cedars-Sinai Medical Center 06/10/2011
CSES7
(see details) 		0108 Dhruv Sareen, Ph.D. (None Entered) Cedars-Sinai Medical Center 06/10/2011
CSES8; abnormal karyotype
(see details) 		0109 Dhruv Sareen, Ph.D. (None Entered) Cedars-Sinai Medical Center 06/10/2011
CSES11; abnormal karyotype
(see details) 		0110 Dhruv Sareen, Ph.D. (None Entered) Cedars-Sinai Medical Center 06/10/2011
CSES12; abnormal karyotype
(see details) 		0111 Dhruv Sareen, Ph.D. (None Entered) Cedars-Sinai Medical Center 06/10/2011
CSES13; abnormal karyotype
(see details) 		0112 Dhruv Sareen, Ph.D. (None Entered) Cedars-Sinai Medical Center 06/10/2011
CSES14; abnormal karyotype
(see details) 		0113 Dhruv Sareen, Ph.D. (None Entered) Cedars-Sinai Medical Center 06/10/2011
CSES15
(see details) 		0114 Dhruv Sareen, Ph.D. (None Entered) Cedars-Sinai Medical Center 06/10/2011
CSES17
(see details) 		0115 Dhruv Sareen, Ph.D. (None Entered) Cedars-Sinai Medical Center 06/10/2011
CSES19
(see details) 		0116 Dhruv Sareen, Ph.D. (None Entered) Cedars-Sinai Medical Center 06/10/2011
CSES20; abnormal karyotype
(see details) 		0117 Dhruv Sareen, Ph.D. (None Entered) Cedars-Sinai Medical Center 06/10/2011
CSES21; abnormal karyotype
(see details) 		0118 Dhruv Sareen, Ph.D. (None Entered) Cedars-Sinai Medical Center 06/10/2011
CSES22; abnormal karyotype
(see details) 		0119 Dhruv Sareen, Ph.D. (None Entered) Cedars-Sinai Medical Center 06/10/2011
CSES23; abnormal karyotype
(see details) 		0120 Dhruv Sareen, Ph.D. (None Entered) Cedars-Sinai Medical Center 06/10/2011
CSES24; abnormal karyotype
(see details) 		0121 Dhruv Sareen, Ph.D. (None Entered) Cedars-Sinai Medical Center 06/10/2011
CSES25
(see details) 		0122 Dhruv Sareen, Ph.D. (None Entered) Cedars-Sinai Medical Center 06/10/2011
UCLA 4
(see details) 		0087 Steven Peckman (None Entered) University of California Los Angeles 02/03/2011
UCLA 5
(see details) 		0088 Steven Peckman (None Entered) University of California Los Angeles 02/03/2011
UCLA 6
(see details) 		0089 Steven Peckman (None Entered) University of California Los Angeles 02/03/2011
ESI-014
(see details) 		0092   (None Entered) BioTime, Inc. 06/02/2011
ESI-017
(see details) 		0093 BioTime, Inc. (None Entered) BioTime, Inc. 06/02/2011
HUES PGD 13; Spinal Muscular Atrophy mutation
(see details) 		0090 Eggan Lab (None Entered) Harvard University 03/15/2011
HUES 48
(see details) 		0053 HSCI iPS Core (None Entered) Harvard University 04/27/2010
HUES 49
(see details) 		0054 HSCI iPS Core (None Entered) Harvard University 04/27/2010
HUES 53
(see details) 		0055 HSCI iPS Core (None Entered) Harvard University 04/27/2010
HUES 65
(see details) 		0056 HSCI iPS Core (None Entered) Harvard University 04/27/2010
HUES 66
(see details) 		0057 HSCI iPS Core (None Entered) Harvard University 04/27/2010
HUES 62
(see details) 		0065 HSCI iPS Core (None Entered) Harvard University 06/03/2010
HUES 63
(see details) 		0066 HSCI iPS Core (None Entered) Harvard University 06/03/2010
HUES 64
(see details) 		0067 HSCI iPS Core (None Entered) Harvard University 06/03/2010
HUES 42
(see details) 		0157 HSCI iPS Core (None Entered) Harvard University 05/31/2012
HUES 44
(see details) 		0158 HSCI iPS Core (None Entered) Harvard University 05/31/2012
HUES 45
(see details) 		0076 HSCI iPS Core (None Entered) Harvard University 09/28/2010
HUES 69
(see details) 		0178 HSCI iPS Core (None Entered) Harvard University 08/07/2012
HUES 68
(see details) 		0176 HSCI iPS Core (None Entered) Harvard University 07/09/2012
HUES 70
(see details) 		0177 HSCI iPS Core (None Entered) Harvard University 07/09/2012
HUES PGD 1; Spinal Muscular Atrophy mutation
(see details) 		0148 Eggan Lab (None Entered) Harvard University 02/24/2012
HUES PGD 3; Duchenne Muscular Dystrophy carrier mutation
(see details) 		0091 Eggan Lab (None Entered) Harvard University 03/15/2011
HUES PGD 10
(see details) 		0179 Eggan Lab (None Entered) Harvard University 09/24/2012
HUES PGD 11; Charcot-Marie-Tooth disease mutation
(see details) 		0094 Eggan Lab (None Entered) Harvard University 06/07/2011
HUES PGD 12; Charcot-Marie-Tooth disease mutation
(see details) 		0095 Eggan Lab (None Entered) Harvard University 06/07/2011
CT1
(see details) 		0068 University of Connecticut Stem Cell Core (None Entered) UNIVERSITY OF CONNECTICUT SCH OF MED/DNT 06/21/2010
CT2
(see details) 		0069 University of Connecticut Stem Cell Core (None Entered) UNIVERSITY OF CONNECTICUT SCH OF MED/DNT 06/21/2010
CT3
(see details) 		0070 University of Connecticut Stem Cell Core (None Entered) UNIVERSITY OF CONNECTICUT SCH OF MED/DNT 06/21/2010
CT4
(see details) 		0071 University of Connecticut Stem Cell Core (None Entered) UNIVERSITY OF CONNECTICUT SCH OF MED/DNT 06/21/2010
SA001
(see details) 		0085 Cellartis AB (None Entered) Cellartis AB 12/17/2010
SA002; abnormal karyotype
(see details) 		0086 Cellartis AB (None Entered) Cellartis AB 12/17/2010
NYUES1
(see details) 		0045 Christoph Hansis, MD, PhD (None Entered) New York University School of Medicine 03/29/2010
NYUES2
(see details) 		0046 Christoph Hansis, MD, PhD (None Entered) New York University School of Medicine 03/29/2010
NYUES3
(see details) 		0047 Christoph Hansis, MD, PhD (None Entered) New York University School of Medicine 03/29/2010
NYUES4
(see details) 		0048 Christoph Hansis, MD, PhD (None Entered) New York University School of Medicine 03/29/2010
NYUES5
(see details) 		0049 Christoph Hansis, MD, PhD (None Entered) New York University School of Medicine 03/29/2010
NYUES6
(see details) 		0050 Christoph Hansis, MD, PhD (None Entered) New York University School of Medicine 03/29/2010
NYUES7
(see details) 		0051 Christoph Hansis, MD, PhD (None Entered) New York University School of Medicine 03/29/2010
CyT49
(see details) 		0041   (None Entered) ViaCyte, Inc. 01/19/2010
UCSF4
(see details) 		0044 Susan Fisher (None Entered) University of California San Francisco 03/12/2010
BJNhem19
(see details) 		0083 Jawaharlal Nehru Centre for Advanced Scientific Research (None Entered) Jawaharlal Nehru Centre for Advanced Scientific Research 12/17/2010
BJNhem20
(see details) 		0084 Jawaharlal Nehru Centre for Advanced Scientific Research (None Entered) Jawaharlal Nehru Centre for Advanced Scientific Research 12/17/2010
RUES3
(see details) 		0042 The Rockefeller University, Ali Brivanlou (None Entered) The Rockefeller University 01/19/2010
MFS5; Marfan Syndrome mutation
(see details) 		0052 Eric Chiao (None Entered) Stanford University 04/27/2010
UCLA 1
(see details) 		0058 Steven Peckman (None Entered) University of California, Los Angeles 04/27/2010
UCLA 2
(see details) 		0059 Steven Peckman (None Entered) University of California, Los Angeles 04/27/2010
UCLA 3
(see details) 		0060 Steven Peckman (None Entered) University of California, Los Angeles 04/27/2010
Lis34_FAP_3; Familial Adenomatous Polyposis mutation
(see details) 		0324 Dalit Ben-Yosef (None Entered) Tel Aviv Sourasky Medical Center 07/16/2015
Lis30_FAP_2; Familial Adenomatous Polyposis mutation
(see details) 		0325 Dalit Ben-Yosef (None Entered) Tel Aviv Sourasky Medical Center 07/16/2015
Lis29_FXS_7; Fragile X mutation
(see details) 		0326 Dalit Ben-Yosef (None Entered) Tel Aviv Sourasky Medical Center 07/16/2015
Lis28_t(Y;14)_2; abnormal karyotype
(see details) 		0327 Dalit Ben-Yosef (None Entered) Tel Aviv Sourasky Medical Center 07/16/2015
Lis23_DMD_5; Duchenne Muscular Dystrophy mutation
(see details) 		0328 Dalit Ben-Yosef (None Entered) Tel Aviv Sourasky Medical Center 07/16/2015
HUES 74
(see details) 		0304 Eggan Lab (None Entered) Harvard University 04/02/2015
UM25-2
(see details) 		0305 Gary D. Smith / University of Michigan (None Entered) University of Michigan 04/02/2015
UM90-14 PGD; Duchenne/Becker Muscular Dystrophy carrier mutations
(see details) 		0306 Gary D. Smith/ University of Michigan (None Entered) University of Michigan 04/02/2015
UM112-2 PGD; adrenoleukodystrophy mutations
(see details) 		0307 Gary D. Smith/ University of Michigan (None Entered) University of Michigan 04/02/2015
GENEA001
(see details) 		0370 Genea Biocells (None Entered) Genea 12/29/2016
GENEA093
(see details) 		0371 Genea Biocells (None Entered) Genea 12/29/2016
GENEA094
(see details) 		0372 Genea Biocells (None Entered) Genea 12/29/2016
GENEA095; abnormal karyotype
(see details) 		0373 Genea Biocells (None Entered) Genea 12/29/2016
GENEA104
(see details) 		0374 Genea Biocells (None Entered) Genea 12/29/2016
GENEA105; abnormal karyotype
(see details) 		0375 Genea Biocells (None Entered) Genea 12/29/2016
GENEA100; Charcot-Marie tooth syndrome 1A mutation
(see details) 		0376 Genea Biocells (None Entered) Genea 12/29/2016
GENEA101; Charcot-Marie tooth syndrome 1A mutation
(see details) 		0377 Genea Biocells (None Entered) Genea 12/29/2016
GENEA099; Splastic paraplegia IV mutation
(see details) 		0378 Genea Biocells (None Entered) Genea 12/29/2016
UM4-9
(see details) 		0352 Gary D. Smith/University of Michigan (None Entered) University of Michigan 01/22/2016
UM4-11
(see details) 		0353 Gary D. Smith / University of Michigan (None Entered) University of Michigan 01/22/2016
UM4-12
(see details) 		0354 Gary D. Smith/University of Michigan (None Entered) University of Michigan 01/22/2016
UM14-3
(see details) 		0355 Gary D. Smith/University of Michigan (None Entered) University of Michigan 01/22/2016
UM126-2
(see details) 		0356 Gary D. Smith/University of Michigan (None Entered) University of Michigan 01/22/2016
UM59-4 PGD; Charcot Marie Tooth, Type 1A mutation
(see details) 		0357 Gary D. Smith/University of Michigan (None Entered) University of Michigan 01/22/2016
UM89-3 PGD; Charcot Marie Tooth, Type 1A mutation
(see details) 		0358 Gary D. Smith/University of Michigan (None Entered) University of Michigan 01/22/2016
UM89-4 PGD; Marfan Syndrome mutation
(see details) 		0359 Gary D. Smith/ University of Michigan (None Entered) University of Michigan 01/22/2016
UM141-6 PGD; Amyotrophic Lateral Sclerosis and Frontotemporal Dementia mutations
(see details) 		0360 Gary D. Smith/University of Michigan (None Entered) University of Michigan 01/22/2016
WCMC 39
(see details) 		0363 Weill Cornell Medical College- Nikica Zaninovic, PhD and Zev Rosenwaks, MD (None Entered) Joan & Sanford I. Weill Cornell Medical College of Cornell University 06/14/2016
WCMC 23
(see details) 		0364 Weill Cornell Medical College - Nikica Zaninovic, PhD and Zev Rosenwaks, MD (None Entered) Joan & Sanford I. Weill Cornell Medical College of Cornell University 06/14/2016
WCMC 13; fragile X mutations
(see details) 		0365 Weill Cornell Medical College- Nikica Zaninovic, PhD and Zev Rosenwaks, MD (None Entered) Joan & Sanford I. Weill Cornell Medical College of Cornell University 06/14/2016
WCMC 11; BRCA1 mutation
(see details) 		0366 Weill Cornell Medical College- Nikica Zaninovic, PhD and Zev Rosenwaks, MD (None Entered) Joan & Sanford I. Weill Cornell Medical College of Cornell University 06/14/2016
WCMC 10
(see details) 		0367 Weill Cornell Medical College - Nikica Zaninovic, PhD and Zev Rosenwaks, MD (None Entered) Joan & Sanford I. Weill Cornell Medical College of Cornell University 06/14/2016
WCMC 9; BRCA2 mutation
(see details) 		0368 Weill Cornell Medical College-Nikica Zaninovic, PhD and Zev Rosenwaks, MD (None Entered) Joan & Sanford I. Weill Cornell Medical Collge of Cornell University 06/14/2016
WCMC 8; BRCA2 mutation
(see details) 		0369 Weill Cornell Medical College- Nikica Zaninovic, PhD - Zev Rosenwaks, MD (None Entered) Joan & Sanford I. Weill Cornell Medical Colleg of Cornell University 06/14/2016
UM76-2
(see details) 		0361 Gary D. Smith/University of Michigan (None Entered) University of Michigan 01/22/2016
UM89-2
(see details) 		0362 Gary D. Smith/University of Michigan (None Entered) University of Michigan 01/22/2016
HUES PGD 17; Brown-Vialetto-Van Laere syndrome mutation
(see details) 		0379 Eggan Lab (None Entered) Harvard University 03/24/2017
UM57-3 PGD; Multiple Endocrine Neoplasia, Type 2A mutation
(see details) 		0380 Gary D. Smith / University of Michigan (None Entered) University of Michigan 03/24/2017
UM66-3 PGD; Aniridia mutation
(see details) 		0381 Gary D. Smith / University of Michigan (None Entered) University of Michigan 03/24/2017
UM89-5 PGD; Charcot Marie Tooth, Type 1A mutation
(see details) 		0382 Gary D. Smith / University of Michigan (None Entered) University of Michigan 03/24/2017
UM103-1 PGD; Huntington's disease mutation
(see details) 		0383 Gary D. Smith / University of Michigan (None Entered) University of Michigan 03/24/2017
UM150-1 PGD; actin nemaline myopathy mutation
(see details) 		0384 Gary D. Smith / University of Michigan (None Entered) University of Michigan 03/24/2017
UCLA 19n
(see details) 		0385 Steven Peckman (None Entered) University of California, Los Angeles 05/09/2017
UCLA 20n
(see details) 		0386 Steven Peckman (None Entered) University of California, Los Angeles 05/09/2017
UM150-3 PGD; Actin Nemaline Myopathy mutation
(see details) 		0387 Gary D. Smith / University of Michigan (None Entered) University of Michigan 06/01/2017
UM153-1 PGD; Adrenoleukodystrophy mutation
(see details) 		0388 Gary D. Smith / University of Michigan (None Entered) University of Michigan 06/01/2017
NYSCF100
(see details) 		0389 The New York Stem Cell Foundation Research Institute (None Entered) The New York Stem Cell Foundation, Inc. 11/20/2017
NYSCF101
(see details) 		0390 The New York Stem Cell Foundation Research Institute (None Entered) The New York Stem Cell Foundation, Inc. 11/20/2017
Elm2
(see details) 		0396 Carol Ware (None Entered) University of Washington 05/09/2018
Elf3
(see details) 		0397 Carol Ware (None Entered) University of Washington 05/09/2018
Elf4
(see details) 		0398 Carol Ware (None Entered) University of Washington 05/09/2018
UM150-4 PGD; Actin Nemaline Myopathy
(see details) 		0391 Gary D. Smith/University of Michigan (None Entered) University of Michigan 05/04/2018
UM152-1 PGS; abnormal karyotype- 47, XX, +21
(see details) 		0392 Gary D. Smith/ University of Michigan (None Entered) University of Michgan 05/04/2018
UM159-1 PGD; Cystic Fibrosis
(see details) 		0393 Gary D. Smith/University of Michigan (None Entered) University of Michigan 05/04/2018
UM161-1 PGD; Niemann-Pick, Type C
(see details) 		0394 Gary D. Smith/University of Michigan (None Entered) University of Michigan 05/04/2018
UM160-3
(see details) 		0395 Gary D. Smith/University of Michigan (None Entered) University of Michigan 05/04/2018
RNJ19; congenital nephrotic syndrome mutation
(see details) 		0126 Reprogenetics, LLC NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: "...characterization of stem cells from embryos discarded due to genetic defects or other abnormalities and the development of new methods for transforming stem cells into other cell types."

Reprogenetics, LLC 06/16/2011
RNJ20; congenital nephrotic syndrome mutation
(see details) 		0127 Reprogenetics, LLC NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: "...characterization of stem cells from embryos discarded due to genetic defects or other abnormalities and the development of new methods for transforming stem cells into other cell types."

Reprogenetics, LLC 06/16/2011
RNJ18; congenital nephrotic syndrome mutation
(see details) 		0128 Reprogenetics, LLC NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: "...characterization of stem cells from embryos discarded due to genetic defects or other abnormalities and the development of new methods for transforming stem cells into other cell types."

Reprogenetics, LLC 06/16/2011
Endeavour-2
(see details) 		0073 Kuldip Sidhu NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: "...for the treatment of diabetes."

Stem Cell Laboratory, Faculty of medicine, University of New South Wales 06/21/2010
MA135
(see details) 		0072 Advanced Cell Technology, Inc. NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: "...to study the process of cell development, and to try to make cells and tissues that can be transplanted into humans to treat various diseases."

Advanced Cell Technology, Inc. 06/21/2010
HUES 1
(see details) 		0014 HSCI iPS Core NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: “These cells will be used to study the embryonic development of endoderm with a focus on pancreatic formation. The long-term goal is to create human pancreatic islets that contain ß cells, the cells that produce insulin, for transplantation into diabetics.”

Harvard University 12/14/2009
HUES 2
(see details) 		0015 HSCI iPS Core NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: “These cells will be used to study the embryonic development of endoderm with a focus on pancreatic formation. The long-term goal is to create human pancreatic islets that contain ß cells, the cells that produce insulin, for transplantation into diabetics.”

Harvard University 12/14/2009
HUES 3
(see details) 		0016 HSCI iPS Core NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: “These cells will be used to study the embryonic development of endoderm with a focus on pancreatic formation. The long-term goal is to create human pancreatic islets that contain ß cells, the cells that produce insulin, for transplantation into diabetics.”

Harvard University 12/14/2009
HUES 5
(see details) 		0018 HSCI iPS Core NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: “These cells will be used to study the embryonic development of endoderm with a focus on pancreatic formation. The long-term goal is to create human pancreatic islets that contain ß cells, the cells that produce insulin, for transplantation into diabetics.”

Harvard University 12/14/2009
HUES 6
(see details) 		0019 HSCI iPS Core NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: “These cells will be used to study the embryonic development of endoderm with a focus on pancreatic formation. The long-term goal is to create human pancreatic islets that contain ß cells, the cells that produce insulin, for transplantation into diabetics.”

Harvard University 12/14/2009
HUES 7
(see details) 		0020 HSCI iPS Core NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: “These cells will be used to study the embryonic development of endoderm with a focus on pancreatic formation. The long-term goal is to create human pancreatic islets that contain ß cells, the cells that produce insulin, for transplantation into diabetics.”

Harvard University 12/14/2009
HUES 8
(see details) 		0021 HSCI iPS Core NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: “These cells will be used to study the embryonic development of endoderm with a focus on pancreatic formation. The long-term goal is to create human pancreatic islets that contain ß cells, the cells that produce insulin, for transplantation into diabetics.”

Harvard University 12/14/2009
HUES 9
(see details) 		0022 HSCI iPS Core NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: “These cells will be used to study the embryonic development of endoderm with a focus on pancreatic formation. The long-term goal is to create human pancreatic islets that contain ß cells, the cells that produce insulin, for transplantation into diabetics.”

Harvard University 12/14/2009
HUES 10
(see details) 		0023 HSCI iPS Core NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: “These cells will be used to study the embryonic development of endoderm with a focus on pancreatic formation. The long-term goal is to create human pancreatic islets that contain ß cells, the cells that produce insulin, for transplantation into diabetics.”

Harvard University 12/14/2009
HUES 11
(see details) 		0024 HSCI iPS Core NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: “These cells will be used to study the embryonic development of endoderm with a focus on pancreatic formation. The long-term goal is to create human pancreatic islets that contain ß cells, the cells that produce insulin, for transplantation into diabetics.”

Harvard University 12/14/2009
HUES 12
(see details) 		0025 HSCI iPS Core NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: “These cells will be used to study the embryonic development of endoderm with a focus on pancreatic formation. The long-term goal is to create human pancreatic islets that contain ß cells, the cells that produce insulin, for transplantation into diabetics.”

Harvard University 12/14/2009
HUES 13
(see details) 		0026 HSCI iPS Core NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: “These cells will be used to study the embryonic development of endoderm with a focus on pancreatic formation. The long-term goal is to create human pancreatic islets that contain ß cells, the cells that produce insulin, for transplantation into diabetics.”

Harvard University 12/14/2009
HUES 14
(see details) 		0027 HSCI iPS Core NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: “These cells will be used to study the embryonic development of endoderm with a focus on pancreatic formation. The long-term goal is to create human pancreatic islets that contain ß cells, the cells that produce insulin, for transplantation into diabetics.”

Harvard University 12/14/2009
HUES 15
(see details) 		0028 HSCI iPS Core NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: “These cells will be used to study the embryonic development of endoderm with a focus on pancreatic formation. The long-term goal is to create human pancreatic islets that contain ß cells, the cells that produce insulin, for transplantation into diabetics.”

Harvard University 12/14/2009
HUES 16
(see details) 		0029 HSCI iPS Core NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: “These cells will be used to study the embryonic development of endoderm with a focus on pancreatic formation. The long-term goal is to create human pancreatic islets that contain ß cells, the cells that produce insulin, for transplantation into diabetics.”

Harvard University 12/14/2009
HUES 17
(see details) 		0030 HSCI iPS Core NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: “These cells will be used to study the embryonic development of endoderm with a focus on pancreatic formation. The long-term goal is to create human pancreatic islets that contain ß cells, the cells that produce insulin, for transplantation into diabetics.”

Harvard University 12/14/2009
HUES 18
(see details) 		0031 HSCI iPS Core NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: “These cells will be used to study the embryonic development of endoderm with a focus on pancreatic formation. The long-term goal is to create human pancreatic islets that contain ß cells, the cells that produce insulin, for transplantation into diabetics.”

Harvard University 12/14/2009
HUES 19
(see details) 		0032 HSCI iPS Core NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: “These cells will be used to study the embryonic development of endoderm with a focus on pancreatic formation. The long-term goal is to create human pancreatic islets that contain ß cells, the cells that produce insulin, for transplantation into diabetics.”

Harvard University 12/14/2009
HUES 20
(see details) 		0033 HSCI iPS Core NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: “These cells will be used to study the embryonic development of endoderm with a focus on pancreatic formation. The long-term goal is to create human pancreatic islets that contain ß cells, the cells that produce insulin, for transplantation into diabetics.”

Harvard University 12/14/2009
HUES 21
(see details) 		0034 HSCI iPS Core NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: “These cells will be used to study the embryonic development of endoderm with a focus on pancreatic formation. The long-term goal is to create human pancreatic islets that contain ß cells, the cells that produce insulin, for transplantation into diabetics.”

Harvard University 12/14/2009
HUES 22
(see details) 		0035 HSCI iPS Core NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: “These cells will be used to study the embryonic development of endoderm with a focus on pancreatic formation. The long-term goal is to create human pancreatic islets that contain ß cells, the cells that produce insulin, for transplantation into diabetics.”

Harvard University 12/14/2009
HUES 23
(see details) 		0036 HSCI iPS Core NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: “These cells will be used to study the embryonic development of endoderm with a focus on pancreatic formation. The long-term goal is to create human pancreatic islets that contain ß cells, the cells that produce insulin, for transplantation into diabetics.”

Harvard University 12/14/2009
HUES 24
(see details) 		0037 HSCI iPS Core NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: “These cells will be used to study the embryonic development of endoderm with a focus on pancreatic formation. The long-term goal is to create human pancreatic islets that contain ß cells, the cells that produce insulin, for transplantation into diabetics.”

Harvard University 12/14/2009
HUES 26
(see details) 		0038 HSCI iPS Core NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: “These cells will be used to study the embryonic development of endoderm with a focus on pancreatic formation. The long-term goal is to create human pancreatic islets that contain ß cells, the cells that produce insulin, for transplantation into diabetics.”

Harvard University 12/14/2009
HUES 27
(see details) 		0039 HSCI iPS Core NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: “These cells will be used to study the embryonic development of endoderm with a focus on pancreatic formation. The long-term goal is to create human pancreatic islets that contain ß cells, the cells that produce insulin, for transplantation into diabetics.”

Harvard University 12/14/2009
HUES 28
(see details) 		0040 HSCI iPS Core NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: “These cells will be used to study the embryonic development of endoderm with a focus on pancreatic formation. The long-term goal is to create human pancreatic islets that contain ß cells, the cells that produce insulin, for transplantation into diabetics.”

Harvard University 12/14/2009
HUES 4
(see details) 		0017 HSCI iPS Core NIH-funded research with this line is limited to research consistent with the following language from the informed consent document: “These cells will be used to study the embryonic development of endoderm with a focus on pancreatic formation. The long-term goal is to create human pancreatic islets that contain ß cells, the cells that produce insulin, for transplantation into diabetics.”

Harvard University 12/14/2009
Lis14_ Alport_3; Alport Syndrome mutation
(see details) 		0340 Dalit Ben-Yosef NIH-funded research with this line is limited to research on Alport Syndrome, consistent with the language from the informed consent document.

Tel Aviv Sourasky Medical Center 07/16/2015
Lis07_AIS_1 (Androgen Insensitivity)
(see details) 		0334 Dalit Ben-Yosef NIH-funded research with this line is limited to research on Androgen Insensitivity, consistent with the language from the informed consent document.

Tel Aviv Sourasky Medical Center 07/16/2015
Lis08_AIS_2 (Androgen Insensitivity)
(see details) 		0335 Dalit Ben-Yosef NIH-funded research with this line is limited to research on Androgen Insensitivity, consistent with the language from the informed consent document.

Tel Aviv Sourasky Medical Center 07/16/2015
Lis10_DMD_1 (Duchenne Muscular Dystrophy)
(see details) 		0337 Dalit Ben-Yosef NIH-funded research with this line is limited to research on Duchenne Muscular Dystrophy, consistent with the language from the informed consent document.

Tel Aviv Sourasky Medical Center 07/16/2015
Lis11_DMD_2 (Duchenne Muscular Dystrophy)
(see details) 		0338 Dalit Ben-Yosef NIH-funded research with this line is limited to research on Duchenne Muscular Dystrophy, consistent with the language from the informed consent document.

Tel Aviv Sourasky Medical Center 07/16/2015
Lis20_DMD_3 (Duchenne Muscular Dystrophy)
(see details) 		0345 Dalit Ben-Yosef NIH-funded research with this line is limited to research on Duchenne Muscular Dystrophy, consistent with the language from the informed consent document.

Tel Aviv Sourasky Medical Center 07/16/2015
Lis22_DMD_4 (Duchenne Muscular Dystrophy)
(see details) 		0347 Dalit Ben-Yosef NIH-funded research with this line is limited to research on Duchenne Muscular Dystrophy, consistent with the language from the informed consent document.

Tel Aviv Sourasky Medical Center 07/16/2015
Lis25_FAP_1 (Familial Adenomatous Polyposis)
(see details) 		0349 Dalit Ben-Yosef NIH-funded research with this line is limited to research on Familial Adenomatous Polyposis, consistent with the language from the informed consent document.

Tel Aviv Sourasky Medical Center 07/16/2015
Lis24_FXS_5 (Fragile X)
(see details) 		0348 Dalit Ben-Yosef NIH-funded research with this line is limited to research on Fragile X, consistent with the language from the informed consent document.

Tel Aviv Sourasky Medical Center 07/16/2015
Lis01_HEFX1(Fragile X)
(see details) 		0329 Dalit Ben-Yosef NIH-funded research with this line is limited to research on Fragile X, consistent with the language from the informed consent document.

Tel Aviv Sourasky Medical Center 07/16/2015
Lis02_FXS_2 (Fragile X)
(see details) 		0330 Dalit Ben-Yosef NIH-funded research with this line is limited to research on Fragile X, consistent with the language from the informed consent document.

Tel Aviv Sourasky Medical Center 07/16/2015
Lis03_FXS_4 (Fragile X)
(see details) 		0331 Dalit Ben-Yosef NIH-funded research with this line is limited to research on Fragile X, consistent with the language from the informed consent document.

Tel Aviv Sourasky Medical Center 07/16/2015
Lis26_FXS_6 (Fragile X)
(see details) 		0350 Dalit Ben-Yosef NIH-funded research with this line is limited to research on Fragile X, consistent with the language from the informed consent document.

Tel Aviv Sourasky Medical Center 07/16/2015
Lis35_Hydrocephaly_1
(see details) 		0323 Dalit Ben-Yosef NIH-funded research with this line is limited to research on hydrocephaly, consistent with language from the informed consent document.

Tel Aviv Sourasky Medical Center 07/16/2015
Lis12_DM_1 (Myotonic Dystrophy)
(see details) 		0339 Dalit Ben-Yosef NIH-funded research with this line is limited to research on Myotonic Dystrophy, consistent with the language from the informed consent document.

Tel Aviv Sourasky Medical Center 07/16/2015
Lis19_DM_2 (Myotonic Dystrophy)
(see details) 		0344 Dalit Ben-Yosef NIH-funded research with this line is limited to research on Myotonic Dystrophy, consistent with the language from the informed consent document.

Tel Aviv Sourasky Medical Center 07/16/2015
Lis17_Connexin_1 (Non Syndromic Deafness)
(see details) 		0342 Dalit Ben-Yosef NIH-funded research with this line is limited to research on Non Syndromic Deafness, consistent with the language from the informed consent document.

Tel Aviv Sourasky Medical Center 07/16/2015
Lis18_Connexin_2 (Non Syndromic Deafness)
(see details) 		0343 Dalit Ben-Yosef NIH-funded research with this line is limited to research on Non Syndromic Deafness, consistent with the language from the informed consent document.

Tel Aviv Sourasky Medical Center 07/16/2015
Lis21_Noonan_1; Noonan syndrome mutation
(see details) 		0346 Dalit Ben-Yosef NIH-funded research with this line is limited to research on Noonan syndrome, consistent with the language from the informed consent document.

Tel Aviv Sourasky Medical Center 07/16/2015
Lis04_Twist (Saethre-Chotzen Syndrome)
(see details) 		0332 Dalit Ben-Yosef NIH-funded research with this line is limited to research on Saethre-Chotzen Syndrome, consistent with the language from the informed consent document.

Tel Aviv Sourasky Medical Center 07/16/2015
Lis09_DYS_1 (Torsion Dystonia)
(see details) 		0336 Dalit Ben-Yosef NIH-funded research with this line is limited to research on Torsion Dystonia, consistent with the language from the informed consent document.

Tel Aviv Sourasky Medical Center 07/16/2015
Lis15_t(1;12); abnormal karyotype
(see details) 		0341 Dalit Ben-Yosef NIH-funded research with this line is limited to research related to the translocation (1,12), consistent with the language from the informed consent document.

Tel Aviv Sourasky Medical Center 07/16/2015
Lis05_t(11,22); abnormal karyotype
(see details) 		0333 Dalit Ben-Yosef NIH-funded research with this line is limited to research related to the translocation (11,22), consistent with the language from the informed consent document.

Tel Aviv Sourasky Medical Center 07/16/2015
Lis27_t(Y;14)_1; abnormal karyotype
(see details) 		0351 Dalit Ben-Yosef NIH-funded research with this line is limited to research related to the translocation (Y,14), consistent with the language from the informed consent document.

Tel Aviv Sourasky Medical Center 07/16/2015
CA1
(see details) 		0137 Andras Nagy NIH-funded research with this line may only be conducted at Mount Sinai Hospital and “other Canadian laboratories affiliated with the Canadian Stem Cell Network for further research or potential clinical use."

Mt Sinai Hosp-Samuel Lunenfeld Research Institute 12/12/2011
CA2
(see details) 		0138 Andras Nagy NIH-funded research with this line may only be conducted at Mount Sinai Hospital and “other Canadian laboratories affiliated with the Canadian Stem Cell Network for further research or potential clinical use."

Mt Sinai Hosp-Samuel Lunenfeld Research Institute 12/12/2011

Total Eligible Lines = 398

* NIH Registration Number:

The NIH registration number should be used on all NIH competing applications and annual progress reports to identify the stem cell line proposed for use. Identify the specific line(s) from the Registry using the NIH Registration Number (e.g., 0001), in the specified location in the application:

  • For grant applications using the SF424(R&R) electronic application packages, section 4 of the PHS398 Cover Page Supplement component provides fields in which to identify approved cell lines.
  • For grant applications using the SF424(R&R) Individual Fellowship electronic application packages, section C of the PHS Fellowship Supplemental Form component provides fields in which to identify approved cell lines.
  • For grant applications using the PHS 398 paper application form, the Human Embryonic Stem Cells section on page 3 provides a location in which to identify approved cell lines.

** On Hold - NIH has received public comment on a proposed change to the definition of �human embryonic stem cells� in the NIH Guidelines for Human Stem Cell Research. While NIH is considering those public comments on the proposed change, this hESC line is currently on hold and should not be used in NIH-funded research. If grantees are currently using any of these lines they may contact the NIH Institute or Center that is funding their project for further information.


Go to NIH Form 2890 Login Page

Go to NIH Stem Cell Information Page


   
Related Resources

    NIH Form 2890:

  • Login Page
    (Authorization Required)
    Contact Us:

  • Email questions to:
    hescregistry@mail.nih.gov

    • (Emails that are offensive or unrelated to stem cells will be deleted.)
 

This page last updated on July 13, 2011 
Content Manager: hescregistry@mail.nih.gov 
Technical Issues: E-mail OER Webmaster